Mark gained his PhD from the University of Cambridge where the use of embryonic stem cells in mammalian functional genomics was pioneered by Professor Sir Martin Evans (Nobel prize for Medicine 2007). Mark has 20 years experience of research and management in this area and was a co-founder of Paradigm Therapeutics Ltd in 1999. Mark was key in driving the company's scientific, operational and corporate growth. Under his guidance, Paradigm established an industrialized mouse knockout and phenotyping capability and was instrumental in securing the CNS collaboration that subsequently led to Paradigm's acquisition by Takeda. He was appointed President & CSO of Takeda Cambridge in March 2007.
Ian joined Paradigm Therapeutics, a genomics-based drug discovery company, in 2003 to establish and lead a newly created Singapore subsidiary as Director of Research. He was responsible for setting up and managing Paradigm's Singapore operation from the outset, creating a South East Asian research arm to complement Paradigm's UK operation. Ian continues to fulfill the role of Singapore site head as Vice President of Research, Takeda Singapore following the acquisition of Paradigm by Takeda in March 2007. Prior to joining Paradigm, Ian held management and research positions in the UK with SmithKline Beecham and subsequently GlaxoSmithKline, where his team provided genetics-based support for drug discovery across a wide range of therapeutic areas. Ian has a PhD in genetics from the University of Leicester in the UK, gained under the direction of Professor Sir Alec Jeffreys, following the award of a Wellcome Trust Prize Scholarship. After completing his doctorate, Ian held a Research Fellowship with the Imperial Cancer Research Fund (now Cancer Research UK) before moving to a commercial research environment. He has nearly 20 years of research experience and 10 years of industry-based scientific management experience.
Jim is a chartered accountant with 15 years professional experience. He worked for PricewaterhouseCoopers in their Cambridge, Bermuda and London offices before joining Paradigm Therapeutics in 2001 to take responsibility for the company's finances. Since then he has overseen its growth and transformation from small biotech to a Takeda group company.